Premium
MedGenome Inc., which is backed by Sequoia Capital, Novo Holdings and LeapFrog Investments among investors, has earmarked $40 million (around ₹329 crore) for acquisitions this financial year through March. In an interview, Mahesh Pratapneni, chief executive and co-founder, said the genomics research startup is targeting to close three deals in the ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
